ClinicalTrials.gg
CompletedNCT07182864Updated Sep 19, 2025

MH004 Ointment in Healthy Adult Volunteers and Participants With Mild to Moderate Atopic Dermatitis

A Phase 1/2 interventional study of MH004 0.1% Ointment and MH004 0.3% Ointment in Atopic Dermatitis (AD), sponsored by Minghui Pharmaceutical (Hangzhou) Ltd. Completed at 1 site in China. Open to participants aged 12 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-19.

Sponsored by Minghui Pharmaceutical (Hangzhou) Ltd (part of Minghui Pharmaceutical) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 8 months after the study started (first participant enrolled Jan 2022, registered Sep 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
12 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Enrollment
98th of 190
160 · median 164
Started
2022
with 21 others
Phase 1/2
15 of 206
5 open now
Registered
162nd of 206
by date

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 98th largest by enrollment of the 190 interventional ones that give a count, is one of 22 that started in 2022, is one of 15 in phase 1/2, and was the 162nd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

This is a Phase I/II Study of MH004 in Healthy Adult Volunteers, participants with Mild to Moderate Atopic Dermatitis.

Read the detailed description

The study includes 2 parts: The first part (Phase I) is the first-in-human trial of MH004, consisting of a single ascending dose (SAD) study and a multiple ascending dose (MAD) study in healthy volunteers. The second part is a multi-center, randomized, double-Blind, vehicle-controlled phase II study to evaluate the safety, tolerability and PK of MH004 Ointment for AD participants, using defined concentrations of the topical cream based on the PK and safety data in healthy volunteers in Phase I.

03

Conditions studied

  • Atopic Dermatitis (AD)

Browse trials for

04

Who can participate

Ages eligible
12 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Phase I: Adults, age 18 - 70 years old, inclusive. Phase II: Adolescents aged ≥ 12 to 17 years, inclusive. Adults, age 18 - 70 years old, inclusive, at time of screening.
  2. Phase II: clinical diagnosis of mild to moderate atopic dermatitis (AD) for at least 6 months prior to Day 1.
  3. Phase II: IGA 2 to 3, affected BSA 3% to 20% (excluding scalp) at the baseline visit.
  4. Participants who agree to discontinue all agents used to treat AD from screening through the final follow-up visit.

    -

Exclusion criteria

Exclusion Criteria:

  1. Unstable course of AD (spontaneously improving or rapidly deteriorating) as determined by the investigator in the 4 weeks prior to baseline.
  2. Concurrent conditions and history of other diseases:

    • .
    • Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before Baseline.
    • Active acute bacterial, fungal, or viral skin infection within 1 week before Baseline.
    • Any other concomitant skin disorder, pigmentation, or extensive scarring that, in the opinion of the investigator, may interfere with the evaluation of AD lesions or compromise participant safety.
    • Presence of AD lesions only on the hands or feet without prior history of involvement of other classical areas of involvement such as the face or the folds.
    • Other types of eczema.
  3. cardiac disease; new cerebral infarction within 6 months from dosing; within 5 years from dosing; low ; severe renal disease on dialysis; liver disease.
  4. Systemic treated within 4 weeks before dosing; immunizations or sedating antihistamines treated within 4 weeks before dosing; other topical treatments for AD within 1 week before dosing.
  5. Previously received Janus kinase (JAK) inhibitors, systemic or topical.
  6. Ultraviolet light therapy or prolonged exposure to UV radiation within 2 weeks before dosing.
  7. Liver function tests: or ALT ≥ 2 × ; alkaline phosphatase and/or > 1.5 × ULN.
  8. Pregnant or lactating participants, or those considering pregnancy.
  9. Alcohol or drug abuse. -
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Phase I. MH004 (0.1%) in healthy volunteers SAD and MAD

    SAD and MAD

    Drug: MH004 0.1% Ointment

  • Experimental
    Phase I: MH004 (0.3%) in healthy volunteers SAD and MAD

    SAD and MAD

    Drug: MH004 0.3% Ointment

  • Experimental
    Phase I: MH004 (1.0%) in healthy volunteers SAD and MAD

    SAD and MAD

    Drug: MH004 1.0% Ointment

  • Experimental
    Phase I: MH004 (3.0%) in healthy volunteers SAD and MAD

    SAD and MAD

    Drug: MH004 3.0% Ointment

  • Experimental
    Phase II. MH004 (0.1%) in Atopic Dermatitis

    28-Day Repeated Dosing in Participants with Mild to Moderate Atopic Dermatitis

    Drug: MH004 0.1% Ointment

  • Experimental
    Phase II. MH004 (0.3%) in Atopic Dermatitis

    28-Day Repeated Dosing in Participants with Mild to Moderate Atopic Dermatitis

    Drug: MH004 0.3% Ointment

  • Experimental
    Experimental: Phase II. MH004 (1.0%) in Atopic Dermatitis

    28-Day Repeated Dosing in Participants with Mild to Moderate Atopic Dermatitis

    Drug: MH004 1.0% Ointment

  • Experimental
    Experimental: Phase II. MH004 (3.0%) in Atopic Dermatitis

    28-Day Repeated Dosing in Participants with Mild to Moderate Atopic Dermatitis

    Drug: MH004 3.0% Ointment

  • Placebo comparator
    Phase I. Vehicle Ointment in healthy volunteers SAD and MAD

    SAD and MAD

    Drug: Vehicle Ointment

  • Placebo comparator
    Phase II. Vehicle Ointment in Atopic Dermatitis

    28-Day Repeated Dosing in Participants with Mild to Moderate Atopic Dermatitis

    Drug: Vehicle Ointment

Interventions

  • MH004 0.1% ointment applied topically to the affected area as a thin film.

  • MH004 0.3% ointment applied topically to the affected area as a thin film.

  • MH004 1.0% ointment applied topically to the affected area as a thin film.

  • MH004 3.0% ointment applied topically to the affected area as a thin film.

  • DrugVehicle Ointment

    Matching vehicle ointment applied topically to the affected area as a thin film.

06

What researchers measure

Primary outcomes

  1. Phase I: Incidence and severity of Treatment-Emergent Adverse Events (Safety and Tolerability)

    Assess incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0 The incidence, nature, and severity of AEs/SAEs including relationship to study treatment from MAD initial study drug administration time of randomization until Day 14 for MAD participants. The incidence, nature, and severity of AEs/SAEs leading to treatment discontinuation from MAD initial study drug administration time of randomisation until Day 7 for MAD participants. Clinically significant changes in laboratory parameters, vital signs, 12-lead ECG, and other safety assessments from initial study drug administration time of randomisation until Day 7 for SAD participants. Clinically significant changes in laboratory parameters, vital signs, 12-lead ECG, and other safety assessments from MAD initial study drug administration time of randomisation until Day 14 for MAD participants.

    Time frame: 1 year

  2. Phase II: Mean Percentage Change From Baseline in EASI Score at Week 4 in Participants Treated With MH004 Ointment

    EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 areas of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.

    Time frame: Baseline and week 4.

Secondary outcomes

  1. Phase I: Characterization of Pharmacokinetics (Cmax) of MH004 Ointment in Healthy Volunteers or Participants With Mild to Moderate Atopic Dermatitis

    Maximum drug concentration (Cmax)

    Time frame: Up to 6 Months

  2. Phase II: Mean Percentage Change From Baseline in EASI Score at Week 2

    EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 areas of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. The severity strata for the EASI are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.

    Time frame: Baseline, Week 2

  3. Percentage of Participants Who Achieve a ≥ 50% or ≥ 75% Improvement From Baseline in EASI (EASI-50 or EASI-75) at Weeks 4

    EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD).

    Time frame: Baseline, Week 4

  4. Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of 0 to 1 Who Have an Improvement of ≥ 2 Points From Baseline at Weeks 4

    IGA is an assessment scale used to determine severity of atopic dermatitis (AD) and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). An IGA responder was defined as a participant achieving an IGA score of 0 to 1 and an IGA score improvement at least 2 from baseline.

    Time frame: Baseline, Week 4

  5. Mean Change From Baseline in the Scoring in Atopic Dermatitis at Week 4

    SCORAD is a clinical tool used to assess the severity (range/severity) and subjective signs/symptoms (such as itching/insomnia) of AD. The degree of the lesion was scored using the nine-point method. The severity was determined by grading the severity of six signs (erythema, edema, exudation/scabbing, epidermal exfoliation, lichenification and skin dryness) on a 0-3 subscale. The assessment of each physical sign was scored at the most representative lesion sites. Subjective symptoms were scored using the Visual Analogue Scale (VAS), with 0= no pruritus (or insomnia), and 10= the most severe pruritus (or insomnia). The total score is the sum of 5+7x severity /2+VAS (Symptoms), and the SCORAD score ranges from 0 to 103 points. The higher the score, the more severe the AD.

    Time frame: Baseline, Week 4

  6. Number of Participants With At Least One Adverse Event (AEs) and as Per Severity

    AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent.

    Time frame: Up to Week 24

07

Study locations

1 site
  • Huashan Hospital Affiliated to Fudan University
    Shanghai, Shanghai Municipality, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Sep 2022, 8 months.

Of 25 industry-sponsored phase 1/2 interventional studies under Dermatitis, Atopic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's 8 months is below that.

Counting every sponsor, half of 29 studies reached it within 22 months; a quarter within 8 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2025
First posted
Sep 19, 2025
StartActual
Jan 6, 2022
Primary completionActual
Sep 8, 2022
CompletionActual
Oct 8, 2022
Last update
Sep 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07182864
Responsible party
Sponsor
First posted
Sep 19, 2025
Start date
Jan 6, 2022
Primary completion
Sep 8, 2022
Completion
Oct 8, 2022
Last update
Sep 19, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MH004

Start the discussion